Clinical trials: Hypertensive Patients
Essential Hypertension
Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension
The study will evaluate the blood pressure lowering effects of two different dosages of the combination of olmesartan and hydrochlorothiazide in patients with moderate or severe high blood pressure.
- Trial name
- NCT00430508
- Testing
- olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets, olmesartan medoxomil/hydrochlorothiazide tablets
- Where
- 55 sites in Bulgaria, Czechia and 5 more
- Volunteers
- 972 people
- Sponsor
- Daiichi Sankyo
Hypertension
Effectiveness and Safety of Combination of Amlodipine and Zofenopril in Hypertensive Patients Versus Each Monotherapy
Study to assess the anti-hypertensive efficacy and safety of the extemporaneous combination of Zofenopril 30 mg in combination with Amlodipine 5 mg or AML 10 mg in lowering the sitting diastolic BP after 8 weeks of treatment in…
- Trial name
- Masolino (NCT05279807)
- Testing
- Zofenopril, Amlodipine
- Where
- Hungary
- Volunteers
- 277 people
- Sponsor
- Menarini International Operations Luxembourg SA
Hypertension
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
The purpose of this study is to evaluate the effect of zilebesiran on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of zilebesiran as add-on therapy.
- Trial name
- KARDIA-2 (NCT05103332)
- Testing
- Indapamide, Amlodipine, Olmesartan
- Where
- 110 sites in United States, Canada and 6 more
- Volunteers
- 663 people
- Sponsor
- Alnylam Pharmaceuticals
Hypertension
Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With Aliskiren
This study will compare the effects of high and low level sodium (salt) diets on blood pressure in patients with hypertension (high blood pressure) who are taking aliskiren 300 mg.
- Trial name
- NCT00441064
- Testing
- Aliskiren
- Where
- 19 sites in United States
- Volunteers
- 132 people
- Sponsor
- Novartis
Hypertension
Telmisartan Tab Hypertension
To assess the efficacy of telmisartan in hypertensive patients with high cardiovascular risk
- Trial name
- NCT00890084
- Testing
- Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)
- Volunteers
- 2,913 people
- Sponsor
- Boehringer Ingelheim
Hypertension, Abdominal Obesity
Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension
Part 1 determined: aliskiren, amlodipine and angiotensin II concentrations in interstitial fluid of fat and skeletal muscle; aliskiren and angiotensin II concentrations, and renin activity and concentration in fat and skeletal…
- Trial name
- NCT00498433
- Testing
- Aliskiren, Amlodipine
- Where
- 2 sites in Germany
- Volunteers
- 46 people
- Sponsor
- Novartis
Hypertension
Nice Morning- Safety and Efficacy Observational Study of Telmisartan in Hypertensive Patients in Multicenters
The purpose of this observational study is to survey the safety and effectiveness of the product under the real condition of usual practice in Taiwanese hypertensive patients.
- Trial name
- NCT00615108
- Where
- 17 sites in Taiwan
- Volunteers
- 3,148 people
- Sponsor
- Boehringer Ingelheim
Hypertension, High Blood Pressure
Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients
This project will evaluate the clinical and cost effectiveness of a novel, multidisciplinary approach to identify and treat pre-clinical cardiac dysfunction (PCCD) in asymptomatic hypertensive patients identified in a single…
- Conditions
- Hypertension, High Blood Pressure, Ventricular Hypertrophy, Diastolic Dysfunction
- Trial name
- NCT00689819
- Testing
- Exercise, Weight Loss, Low Sodium Diet
- Where
- United States
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Wayne State University
Hypertension
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
The purpose of this study is to evaluate in a randomized, double-blind fashion, the long-term safety, tolerability and efficacy profile of aliskiren compared to the active comparator enalapril in children, 6 - 17 years old with…
- Trial name
- NCT01151410
- Testing
- Aliskiren, Enalapril
- Where
- 36 sites in United States, Guatemala and 5 more
- Volunteers
- 208 people
- Sponsor
- Novartis Pharmaceuticals
Severe Hypertension
Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive Patients
This study assessed the safety, tolerability, and efficacy of LCZ696 in severe hypertensive Japanese patients
- Trial name
- NCT01646671
- Testing
- LCZ696
- Where
- 9 sites in Japan
- Volunteers
- 35 people
- Sponsor
- Novartis Pharmaceuticals
Glaucoma
Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to assess the safety and efficacy of Travoprost 0.004% and Tafluprost 0.0015% in patients with primary open angle glaucoma or ocular hypertension when both medications are administered in the evening.
- Trial name
- NCT00966940
- Testing
- Travoprost 0.004% ophthalmic solution (TRAVATAN), Tafluprost 0.0015% ophthalmic solution
- Volunteers
- 51 people
- Sponsor
- Alcon Research
Diabetes, Hypertension
Adherence and Intensification of Medications (AIM) Implementation Study
Background: Good blood pressure (BP) control among patients with diabetes is essential in preventing diabetes complications and has been found to be not only cost-effective but cost-saving.
- Trial name
- NCT00495794
- Testing
- Clinical pharmacist-based intervention
- Where
- United States
- Volunteers
- 4,622 people
- Sponsor
- US Department of Veterans Affairs
Hypertension, Cardiovascular Diseases
Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients
The study is designed to evaluate the effect of treatment with Micardis/MicardisPlus on blood pressure and its ability to reduce different indicated cardiovascular risks.
- Trial name
- NCT00904371
- Where
- 36 sites in Slovenia
- Volunteers
- 211 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure
Randomized, double-blind, parallel group, multicenter study of subjects with Stage 1 or 2 essential hypertension who are not at target blood pressure (<140/90mmHg) at Baseline.
- Trial name
- NCT00624065
- Testing
- carvedilol controlled release/lisinopril
- Where
- 76 sites in United States
- Volunteers
- 348 people
- Sponsor
- GlaxoSmithKline
Hypertension
A Study to Evaluate Whether Losartan Protects the Kidney in Hypertensive Diabetic Participants With Microalbuminuria (MK0954-365 AM1)
This study will evaluate whether losartan protects the kidney in hypertensive Type II diabetic participants with microalbuminuria.
- Trial name
- NCT01390415
- Volunteers
- 136 people
- Sponsor
- Organon and Co
Hypertension
Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients
Open-label, inteRventional clinical Trial to assess EffIcacy and safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients.
- Trial name
- ARTEMISIA (NCT06104423)
- Testing
- Nebivolol 5 mg, Ramipril 2.5/5/10 mg
- Where
- Hungary
- Volunteers
- 266 people
- Sponsor
- Menarini International Operations Luxembourg SA
High Blood Pressure, Metabolic Syndrome
Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome
The purpose of this study was to determine the effects of Aliskiren on insulin resistance (IR) and endothelial dysfunction (ED) in patients with high blood pressure and metabolic syndrome.
- Conditions
- High Blood Pressure, Metabolic Syndrome, Insulin Resistance, Endothelial Dysfunction
- Trial name
- NCT00417170
- Testing
- Aliskiren, Amlodipine
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal
This study was specifically designed to provide additional information on the mechanism of action of direct renin inhibition postulating the higher-level RAS cascade inhibition.
- Trial name
- ASSERTIVE (NCT00865020)
- Testing
- Aliskiren, Telmisartan
- Where
- 16 sites in Brazil, Canada and 14 more
- Volunteers
- 822 people
- Sponsor
- Novartis
Hypertension
Telmisartan 80mg+Hydrochlorothiazide (HCTZ) 25 mg in Hypertension: an Observational Study
It is a national, retrospective , observational study in hypertensive patients treated for at least 8 weeks with the fixed dose combination of telmisartan 80 mg and hydrochlorothiazide 25 mg.
- Trial name
- NCT00909038
- Where
- 915 sites in France
- Volunteers
- 2,411 people
- Sponsor
- Boehringer Ingelheim
Open Angle Glaucoma, Ocular Hypertension
Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients
The objective of the study is to assess the efficacy and safety of T2347 (Latanoprost 0.005% + Timolol 0.5% unpreserved eye drops) versus Xalacom® in ocular hypertensive or glaucomatous patients initially treated, stabilised by…
- Trial name
- NCT02278614
- Testing
- T2347, Xalacom
- Where
- France
- Volunteers
- 242 people
- Sponsor
- Laboratoires Thea